Ionis Pharmaceuticals confirmed it has stopped development of an investigational Alzheimer’s candidate intended for people with Down syndrome. The company said the decision followed an internal review of program data and development priorities; Ionis communicated the termination to investors and stakeholders via company statement and press reporting. The discontinuation removes a therapy candidate aimed at a high‑risk, underserved patient population and will refocus Ionis’ resources on other pipeline programs. The action underscores continued attrition in early neurodegeneration programs and the challenges of translating mechanism‑based hypotheses into clinically meaningful outcomes in genetically defined subgroups.